FDA Outlines 2019 Compounding Priorities

April 4, 2019

The U.S. Food and Drug Administration (FDA) on April 3 released a statement outlining its compounding priorities for 2019.

“We’ve taken significant new steps to modernize and clarify our policies related to the quality of compounding in an effort to ensure continued access to compounded drugs for patients who need them, while also protecting patients from the risks of contaminated or otherwise harmful products,” FDA said in the release.

These are some of the agency’s priorities: 


Read the full release.